Related Experiment Video
Updated: Aug 7, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors
Shahnaz D Vellani1, Anthony Nigro1, Shangari Varatharajan1
1Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.
Abstract:
Evasion of innate immunity represents a frequently employed method by which tumor cells survive and thrive. Previously, the development of immunotherapeutic agents capable of overcoming this evasion has realized pronounced clinical utility across a variety of cancer types. More recently, immunological strategies have been investigated as potentially viable therapeutic and diagnostic modalities in the management of carcinoid tumors. Classic treatment options for carcinoid tumors rely upon surgical resection or non-immune pharmacology. Though surgical intervention can be curative, tumor characteristics, such as size, location, and spread, heavily limit success. Non-immune pharmacologic treatments can be similarly limited, and many demonstrate problematic side effects. Immunotherapy may be able to overcome these limitations and further improve clinical outcomes. Similarly, emerging immunologic carcinoid biomarkers may improve diagnostic capabilities. Recent developments in immunotherapeutic and diagnostic modalities of carcinoid management are summarized here.
Insights
Immunotherapy and immunologic biomarkers show promise for treating and diagnosing carcinoid tumors, potentially overcoming limitations of current surgical and pharmacologic approaches.
Area of Science:
- Oncology
- Immunology
- Tumor Biology
Background:
- Tumor cells frequently evade innate immunity for survival.
- Immunotherapy has shown clinical utility in various cancers.
- Carcinoid tumors traditionally managed with surgery or non-immune pharmacology.
Purpose of the Study:
- To review recent developments in immunologic strategies for carcinoid tumor management.
- To explore immunotherapy as a therapeutic option for carcinoid tumors.
- To discuss emerging immunologic biomarkers for carcinoid tumor diagnosis.
Main Methods:
- Literature review of immunotherapeutic and diagnostic modalities.
- Analysis of current treatment limitations for carcinoid tumors.
- Exploration of immune evasion mechanisms in cancer.
Main Results:
- Immunotherapy offers potential to overcome limitations of surgery and pharmacology in carcinoid tumors.
- Immunologic biomarkers may enhance diagnostic capabilities for carcinoid tumors.
- Recent advancements suggest immunotherapy can improve clinical outcomes.
Conclusions:
- Immunotherapy represents a promising therapeutic avenue for carcinoid tumors.
- Immunologic biomarkers are emerging as valuable diagnostic tools.
- Integrating immunologic approaches may significantly advance carcinoid tumor management.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...